Clinical trial update: Focus on the ONTARGET study

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 901-908

  Fitchett, David ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

RAAS modulation; Ramipril; Telmisartan; Vascular protection

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; MONOTHERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 38349053972     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Berl T, Hunsicker LG, Lewis JB, et al. 2003. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med, 138:542-9.
2. Brenner BM, Cooper ME, de Z, et al. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl Med, 345:861-9.
3. Brown NJ, Kumar S, Painter CA, et al. 2002. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension, 40:859-65.
4. Carlberg B, Samuelsson O, Hjalmar Lindholm L. 2004. Atenolol in hypertension: is it a wise choice? Lancet, 364:1684-9.
5. Dagenais GR, Pogue J, Fox K, et al. 2006. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet, 368:581-8.
6. Dahlof B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995-1003.
7. Danchin N, Cucherat M, Thuillez C, et al. 2006. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med, 166:787-96.
8. Demers C, McMurray JJ, Svedberg K, et al. 2004. Impact of Candesartan in Preventing Myocardial Infarction: Results of the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) Programme. Circulation, 110(Suppl 111):111-514.
9. DeRosa G, Ragonesi PD, Mugellini A et al. 2004. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double- blind, placebo-controlled 12-month study. Hypertens Res, 27:457-64.
10. Dol F, Martin G, Staels B, et al. 2001. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol, 38:395-405.
11. Dzau VJ. 2001. Tissue angiotensin and the pathobiology of vascular disease: a unifying hypothesis. Hypertension, 37:1047-52.
12. Dzau VJ. 2005. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens, 23(Suppl 1):S9-S17.
13. Dzau VJ. 1998. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J, 19(Suppl J):J2-J6.
14. Flather MD, Yusuf S, Kober L, et al. 2000. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infirction Collaborative Group [see comments]. Lancet, 355:1575-81.
15. Grafe M, Auch-Schwelk W, Zakrzewicz A, et al. 1997. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res, 81: 904-11.
16. Granger CB, McMurray JJ, Yusuf S, et al. 2003. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 362:772-6.
17. Horiuchi M, Akishita M, Dzau VJ. 1999. Recent progress in Angiotensin type 2 receptor research in the cardiovascular system. Hypertension, 33:621.
18. Hornig B, Kohler C, Drexler H. 1997. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation, 95:1115-18.
19. Julius S, KJeldsen SE, Weber M, et al. 2004. Outcomes in patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363:2022-31.
20. Kim MP, Zhou M, Wahl LM. 2005. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol, 78:195-201.
21. Kurtz TW, Pravenek M. 2004. Antidiabetic mechanisms of ACE inhibitors and AII receptor antagonists: beyond the renin-angiotensin system. J Hypertens, 22:2253-61.
22. Levy BI. 2004. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implicvations for the therapeutic blockade of the renin angiotensin system. Circulation, 109:8-13.
23. Matsubara H. 1998. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal disease. Circ Res, 83:1182-91.
24. McKelvie RS, Yusuf S, Pericak D, et al. 1999. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation, 100:1056-64.
25. McMurray JJ, Ostergren J, Swedberg K, et al. 2003. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 362:767-71.
26. Murphey L, Vaughan D, Brown N. 2003. Contribution of bradykinin to the cardioprotective effects of ACE inhibitors. Euro Heart J Suppl, 5(Suppl A):A37-A41.
27. Ohishi M, Ueda M, Rakugi H, et al. 1999. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J Hypertens, 17:547-53.
28. Parving HH, Lehnert H, Brochner M, et al. 2001. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 345:870-8.
29. Pfeffer MA, Braunwald E, Moye LA, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after f infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med, 327:669-77.
30. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. 2003 a. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 349:1893-906.
31. Pfeffer MA, Swedberg K, Granger CB, et al. 2003b. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362:759-66.
32. Rutherford JD, Pfeffer MA, Moye LA, et al. 1994. Effects of captopril on ischemic events after myocardial infirction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation, 90:1731-8.
33. Strauss MH, Hall AS. 2006. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation, 114:838-54.
34. Strehlow K, Wasserman S, Bohm M, et al. 2000. Angiotensin AT1 receptor over expression in hypercholesterolemia. Ann Med, 32:386-9.
35. Teo K, Yusuf S, Sleight P, et al. 2004. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J, 148:52-61.
36. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. 2003. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPAstudy). Lancet, 362:782-8.
37. The PEACE Investigators. 2004. Angiotensin-Converting-Enzyme Inhibitionin Stable Coronary Artery Disease. N Engl J Med, 351:2058-68.
38. The SOLVD Investigators. 1992. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med, 327:685-91.
39. Turnbull F, Neal B, Algert C, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. 2005. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med, 165:1410-9.
40. Vaughan DE. 2001. Angiotensin, fibrinlysis and vascular homeostasis. Am J Cardiol, 87:24.
41. Verdecchia P, Reboldi G, Angeli F, et al. 2005. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention [In Process Citation]. Hypertension, 46:386-92.
42. Wagenaar LJ, Voors AA, Buikema H, et al. 2002. Angiotensin receptors in the cardiovascular system. Can J Cardiol, 18:1339.
43. Yusuf S, Sleight P, Pogue J, et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342:145-53.